Gad Soffer Sells 12,674 Shares of Atara Biotherapeutics Inc (ATRA) Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) EVP Gad Soffer sold 12,674 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $15.16, for a total transaction of $192,137.84. Following the completion of the sale, the executive vice president now owns 259,527 shares of the company’s stock, valued at approximately $3,934,429.32. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Gad Soffer also recently made the following trade(s):

  • On Friday, March 10th, Gad Soffer sold 2,500 shares of Atara Biotherapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00.

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded up 0.33% during midday trading on Friday, hitting $15.15. 86,898 shares of the stock traded hands. The company’s market capitalization is $440.70 million. Atara Biotherapeutics Inc has a 52 week low of $12.45 and a 52 week high of $25.73. The firm’s 50-day moving average is $17.02 and its 200 day moving average is $16.84.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/gad-soffer-sells-12674-shares-of-atara-biotherapeutics-inc-atra-stock/1370372.html

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.35. Equities analysts forecast that Atara Biotherapeutics Inc will post ($3.83) earnings per share for the current year.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

COPYRIGHT VIOLATION WARNING: This story was published by Zolmax and is the property of of Zolmax. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://zolmax.com/investing/gad-soffer-sells-12674-shares-of-atara-biotherapeutics-inc-atra-stock/1370372.html.

Several institutional investors have recently added to or reduced their stakes in ATRA. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Atara Biotherapeutics during the first quarter valued at approximately $132,000. Elkfork Partners LLC bought a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $135,000. DekaBank Deutsche Girozentrale bought a new position in Atara Biotherapeutics during the first quarter valued at approximately $185,000. BlackRock Inc. increased its position in Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the biotechnology company’s stock valued at $272,000 after buying an additional 6,597 shares in the last quarter. Finally, American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 77.48% of the company’s stock.

ATRA has been the subject of several research reports. Citigroup Inc set a $10.00 price objective on shares of Atara Biotherapeutics and gave the company a “sell” rating in a research report on Thursday, March 16th. Canaccord Genuity restated a “buy” rating and issued a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Finally, Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Three analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $24.00.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Gad Soffer Sells 12,674 Shares of Atara Biotherapeutics Inc  Stock
Gad Soffer Sells 12,674 Shares of Atara Biotherapeutics Inc Stock
Nathu R. Puri Acquires 37,656 Shares of Cenveo, Inc.  Stock
Nathu R. Puri Acquires 37,656 Shares of Cenveo, Inc. Stock
Five Point Holdings LLC  Insider Purchases $196,000.00 in Stock
Five Point Holdings LLC Insider Purchases $196,000.00 in Stock
Marriott International Inc  Shares Bought by Swiss National Bank
Marriott International Inc Shares Bought by Swiss National Bank
Swiss National Bank Purchases 101,200 Shares of Leggett & Platt, Inc.
Swiss National Bank Purchases 101,200 Shares of Leggett & Platt, Inc.
Credit Suisse Group AG Reiterates Outperform Rating for Autodesk, Inc.
Credit Suisse Group AG Reiterates Outperform Rating for Autodesk, Inc.


Leave a Reply

 
© 2006-2017 Zolmax.